Zymeworks Net Income 2016-2022 | ZYME

Zymeworks net income from 2016 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Zymeworks Annual Net Income
(Millions of US $)
2021 $-212
2020 $-181
2019 $-145
2018 $-37
2017 $-11
2016 $-34
2015 $-19
Zymeworks Quarterly Net Income
(Millions of US $)
2022-06-30 $-65
2022-03-31 $-73
2021-12-31 $-39
2021-09-30 $-61
2021-06-30 $-68
2021-03-31 $-45
2020-12-31 $-38
2020-09-30 $-73
2020-06-30 $-39
2020-03-31 $-31
2019-12-31 $-72
2019-09-30 $-30
2019-06-30 $-29
2019-03-31 $-14
2018-12-31 $9
2018-09-30 $-19
2018-06-30 $-6
2018-03-31 $-21
2017-12-31 $33
2017-09-30 $-16
2017-06-30 $-11
2017-03-31 $-16
2016-12-31 $-11
2016-09-30 $-12
2016-06-30 $-7
2016-03-31 $-3
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.584B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $151.446B 9.24
GSK (GSK) United Kingdom $72.652B 9.59
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.227B 19.16
Ginkgo Bioworks Holdings (DNA) United States $3.880B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.620B 24.32
Biohaven (BHVN) United States $1.283B 0.00
Emergent Biosolutions (EBS) United States $0.681B 5.35
ADC Therapeutics SA (ADCT) Switzerland $0.419B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.066B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00